Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Uranium Energy Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Uranium Energy Corp trades at $10.38 (market cap $5.21B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.7× Uranium Energy Corp's market cap, and Uranium Energy Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UEC | |
|---|---|---|
Market Cap | $39.89B | $5.21B |
Sector | Health | Energy |
52-Week High | $491.22 | $20.14 |
52-Week Low | $278.09 | $6.59 |
Enterprise Value | $38.15B | $4.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
UEC trades at $10.53, up 3.64% today, but technical indicators show a bearish trend with strong selling pressure. The company reported widening losses with negative net income margins and zero revenue in recent quarters, though it maintains $794 million in liquid assets and no debt. Analyst consensus remains overwhelmingly bullish with 87.5% buy ratings, citing strategic positioning in uranium production.
Investment outlook hinges on execution of production ramp-ups and uranium price recovery. Key opportunities include strategic assets and strong liquidity, while risks involve persistent losses, regulatory delays, and volatile commodity prices. The stock faces near-term pressure from weak fundamentals despite long-term nuclear energy tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
